Evolus, Inc.
Evolus is a global performance beauty company serving licensed aesthetic practitioners in the cash-pay medical aesthetics market, where consumers pay directly for products. Its commercial products include Jeuveau, an injectable botulinum toxin type A for temporary improvement of frown lines in adults, and Evolysse, a collection of injectable hyaluronic acid gels for aesthetic treatments. Evolysse Form and Smooth are available in the United States. The product lines serve the injectable neurotoxin and dermal filler categories. Evolus earns money by commercializing and distributing its products to aesthetic practitioners. It holds licensing and distribution rights for Jeuveau in specified territories and exclusive U.S. and European rights to commercialize and distribute Evolysse products. Daewoong manufactures and supplies Jeuveau, while Symatese manufactures and supplies Evolysse. Evolus is headquartered in Newport Beach, California.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $EOLS in the last 30 days.
See all $EOLS insider activity →Evolus Inc. (EOLS) reaffirmed its 2026 revenue guidance, citing strong Q3 market trends. The company expects Sculpt's 2027 launch and international expansion to drive growth in 2028. The update was shared at the Stifel 2026 Healthcare Conference.
Evolus (EOLS) set a 2028 revenue target of $450M-$500M, reaffirming 2026 revenue guidance of $330M-$337M. CEO David Moatazedi highlighted four consecutive quarters of positive adjusted EBITDA and portfolio growth.
Evolus (EOLS) reported Q3 EPS of -$0.19, missing estimates by $0.13, while revenue of $77.9M exceeded expectations. The stock is down 1.58% over 3 months but up 9.69% over 12 months. InvestingPro rates its financial health as 'good performance'.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning EOLS (Evolus, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent EOLS coverage spans earnings, financial news and regulation.
Guidance reaffirmation may support the stock price, while the announced product launch could add upside.
The new revenue guidance provides a clear outlook for Evolus, setting expectations for growth over the next two years.
Evolus reported a earnings miss, likely prompting short-term downside pressure.
Evolus reaffirmed its 2026 outlook with solid revenue growth and positive adjusted EBITDA.
Shares fell 2.5% on the news, reflecting modest downside pressure as investors weigh the cost and early‑stage nature of the program.
AlphAI scores every news story that mentions EOLS with an AI model for sentiment and relevance, and aggregates insider trades from Evolus, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Evolus Inc. (EOLS) reaffirmed its 2026 revenue guidance, citing strong Q3 market trends. The company expects Sculpt's 2027 launch and international expansion to drive growth in 2028. The update was shared at the Stifel 2026 Healthcare Conference.
Evolus (EOLS) set a 2028 revenue target of $450M-$500M, reaffirming 2026 revenue guidance of $330M-$337M. CEO David Moatazedi highlighted four consecutive quarters of positive adjusted EBITDA and portfolio growth.
Evolus (EOLS) reported Q3 EPS of -$0.19, missing estimates by $0.13, while revenue of $77.9M exceeded expectations. The stock is down 1.58% over 3 months but up 9.69% over 12 months. InvestingPro rates its financial health as 'good performance'.
Evolus, Inc. (EOLS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Evolus Reports Third Quarter 2026 Financial Results with 13% Year-Over-Year Revenue Growth; Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year 2026 Financial Outlook • Global Net Revenue of $78.0 Million for the Third Quarter of 2026, an Incre
Evolus Inc. (EOLS) has entered an option agreement with a private company to develop an injectable hair restoration treatment. The company will pay $1.5 million upfront and support development, with an option to acquire the program. Clinical trials are expected to start after 2027. Shares of Evolus were down 2.5% to $7.32.
Evolus (EOLS) shares dropped after the FDA issued a warning about an Instagram post promoting its Jeuveau product, stating it misleads consumers and may violate federal law. The post was removed following the warning. The FDA's action highlights regulatory risks for pharmaceutical marketing on social media.
Evolus (EOLS) reported Q2 2026 revenue of $84.1M, up 21% YoY, and positive Adjusted EBITDA of $4.7M. The company raised full-year revenue guidance to $330M-$337M and adjusted gross profit margin guidance to 67.0%-67.5%. Evolus expanded its customer base and loyalty program, while investing in new product launches and partnerships.
Pro-Dex (PDEX) rose 18% to $77 on FY'26 results, with net sales up 16% to $77.5M. Odyssey (ODTX) gained 8% to $29.05, reporting a Q2 loss of $52.8M. Evolus (EOLS) climbed 2% to $9.31, with Q2 revenue up 21% to $84.1M. Biofrontera (BFRI) increased 6% to $1.63, with Q2 product revenue up 32.9%. Alpha Tau (DRTS) hit $15.17, reporting a Q2 loss of $68.8M.
MOATAZEDI DAVID (See Remarks) sold 105,108 shares of Evolus, Inc. (EOLS) at $9.04 ($0.95M total) on 2026-09-02.
RenovoRx (RNXT) rose 15% to $1.97 on positive Phase 3 trial data. Evolus (EOLS) hit $9.15 after 21% revenue growth. Crinetics (CRNX) reached $85.01 ahead of $10B Vertex (VRTX) acquisition. Apogee (APGE) hit $135.08 before $10.9B AbbVie (ABBV) deal. All hit 52-week highs on August 31, 2026.
